Bahasa

   Home      Contact

MEDICAL INFO

1. Postgraduate Medical Information for the Medical Practitioners (FAQ)

 Breakthrough in the Treatment of Rheumatoid Factor Positive Rheumatoid Arthritis by the Step-down Bridge Protocol of Intravenous and Oral Combination of 6 Immunosuppressants
Download

Breakthrough in the Treatment of biopsy-proven Lupus Nephritis by the Step-down Bridge Protocol of Intravenous and Oral Combination of 6 Immunosuppressants (FAQ)
Download

Breakthrough in the Treatment of NSAID-refractory Ankylosing Spondylitis by the Step-down Bridge Protocol of Intravenous and Oral Combination of 6 Immunosuppressants (FAQ)
 Download
 

2. Postgraduate Medical Information for Rheumatologists

2.1.Abstracts
Seven-years Outcome of Rheumatoid Factor Positive Rheumatoid Arthritis after Treatment with the Step-down Bridge Protocol of Intravenous and Oral Combination of 5 Immunosuppressants.
Download

Seven-years Outcome of Biopsy-proven Lupus Nephritis after Treatment with the Step-down Bridge Protocol of Intravenous and Oral Combination of 5 Immunosuppressants - Prospective Observational Analysis of Efficacies and Adverse Effects.
 Download

Six-years Outcome of NSAID-refractory Ankylosing Spondylitis after Treatment with the Step-down Bridge Protocol of Intravenous and Oral Combination of 5 Immunosuppressants.
 Download

2.2. Protocols
Postgraduate Rheumatology Information for the Rheumatologists
Breakthrough in the Treatment of Rheumatoid Factor Positive Rheumatoid Arthritis by the Step-down Bridge Protocol of Intravenous and Oral Combination of 6 Immunosuppressants
 Download

Breakthrough in the Treatment of NSAID-refractory Ankylosing Spondylitis by the Step-down Bridge Protocol of Intravenous and Oral Combination of 6 Immunosuppressants
Download

Breakthrough in the Treatment of biopsy-proven Lupus Nephritis by the Step-down Bridge Protocol of Intravenous and Oral Combination of 6 Immunosuppressants
 Download

3. Myths on RF+FA, NSAID Refractory AS, and Biopsy-proven Lupus Nephritis
In this section you will find 3 of Myths on RF+RA, NSAID-refractory
AS, and Biopsy-proven Lupus Nephritis in the lay and medical communities of the world. However, these myths are refuted by the SBP-5-IMNs in the treatment of RF+ RA, NSAID-refractory AS, and Biopsy-proven Lupus Nephritis.

Review of the Outcome of the Treatment of Lupus Nephritis with the Step-down Bridge Protocol of Intravenous and Oral Combination of 5 Immunosuppressants (SBP-5-IMNs)
 › more
Review of the Outcome of the Treatment of NSAID-refractory Ankylosing Spondylitis (AS) with the Step-down Bridge Protocol of Intravenous and Oral Combination of 5 Immunosuppressants (SBP-5-IMNs)
 › more
Review of the Outcome of the Treatment of Rheumatoid Factor positive (RF+) Rheumatoid Arthritis (RA)
 › more

4. Prognosis Index
The Step-down Bridge Protocol of Intravenous and Oral Combination of 6 Immunosuppressants (SBP-6-IMNs) is inclined to fail when Prognosis Index is > 5.
 Download

5. Postgraduate Refreshing and Update for the Medical Practitioners (FAQ)

5.1. Short, Medium, and Long-term Outcome of Chronic Gout by Treatment of Acute/Chronic Gouty Arthritis and Hyperuricemia (FAQ)
 Download

5.2. Lifetime Treatment and Prevention of Osteoporosis
Lifetime Treatment and Prevention of Osteoporosis (FAQ)
Download

6. Revised Guideline

Proposed Revised Step-down Bridge Combination of 5 Immunosuppressants in the Therapy of Autoimmune Diseases - Rheumatoid Arthritis
 Download
Download
Download
Download


  Email This Page   Print This Page
 
NEWS & EVENTS

LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

16.11.2005
MabThera – a unique approach providing lasting benefits for patients with rheumatoid arthritis

Comprehensive long-term clinical success achieved in difficult-to-treat patients following just two administrations, two weeks apart
 › more
 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.09.2005
Roche files first rheumatoid arthritis indication for MabThera in Europe

MabThera: a medicine used to treat non-Hodgkin's lymphoma

MabThera delivers significant and sustained relief from symptoms in patients with difficult-to-treat rheumatoid arthritis.
› more
 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.04.2005
MabThera significantly improves symptoms in patients with rheumatoid arthritis who inadequately responded to anti-TNFα therapies

Third large randomised trial to evaluate efficacy and safety of MabThera in RA

Roche, Genentech and Biogen Idec announced today that REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its primary endpoint in the group of patients with the most difficult-to-treat rheumatoid arthritis (RA).
 › more

Legal Disclamer
Legal Disclaimer

Copyright ©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases.

This Web site was developed in 2005 as a service provided by the WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases. This Web site provides selected information available about lupus and arthritis. It is important that public see a healthcare professional for detailed information about medical conditions and treatment. This information is not intended to be a substitute for the advice of a healthcare professional, or a recommendation for any particular treatment plan. The WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases has made and will continue to make efforts to include accurate and up-to-date information on this Web site.

If you have any questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
 

 
Supported by PT Roche Indonesia